The EACH study assessed the efficacy of oxaliplatin , @-fluorouracil , and leucovorin ( the FOLFOX@ regimen ) compared with doxorubicin alone in terms of overall survival ( OS ) , progression-free survival ( PFS ) , and safety in patients with advanced hepatocellular carcinoma ( HCC ) .